Shyamakant Giri has been appointed as Group Chief Executive Officer at Apothecon Pharmaceuticals, where he will lead the group’s India and US operations across complex chemistry and high potency API businesses. The company announced the appointment through a post via LinkedIn.
Giri joined Apothecon Group in May 2026 and will oversee operations across Apothecon Pharmaceuticals in India and Navinta in the United States, with a focus on strategic growth, research driven capabilities and operational integration.
Previously, he served as Chief Executive Officer (CEO) at Gland Pharma from January 2025 to April 2026, leading operations across manufacturing sites in India and Europe while driving the company’s injectable and biologics CDMO business.
Before that, he worked at Amneal Pharmaceuticals as Managing Director (MD) and President from June 2022 to January 2025, overseeing expansion across India, Africa, Gulf, CIS, LATAM, China and South Asian markets.
Earlier, Giri was Chief Executive Officer (CEO) at Rivaara Labs from June 2020 to May 2022, where he led expansion in diagnostics, molecular testing and healthcare technology initiatives during the pandemic period.
He also spent more than 17 years at Abbott across multiple leadership roles between 2002 and 2020, including General Manager and Country Head for India Region and Africa, Director EPD Hospital Business and Country Manager for AbbVie Business in India.
Earlier in his career, Giri worked at Wockhardt as Product Manager from January 2001 to November 2002 and Regional Sales Manager from April 1999 to December 2000.
